FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:2707-2709 June 22, 2006 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Tashkin, D. P. PubMed Citation

Clinically significant interstitial lung disease affects patients with systemic sclerosis (scleroderma) and is a cause of morbidity and mortality in approximately 40 percent of these patients.¹ Management of this condition remains difficult and controversial.^2,3 In this issue of the Journal, Tashkin and colleagues⁴ report the results of a multicenter, placebo-controlled trial of oral cyclophosphamide in patients with well-defined, symptomatic scleroderma-related interstitial lung disease and alveolitis. They document small but statistically significant improvements in lung function and symptoms with cyclophosphamide administered over the course of one year — the first positive results of a placebo-controlled trial in this field.

How should . . . [Full Text of this Article]

Source Information

From the Division of Pulmonary and Critical Care Medicine (F.J.M.) and the Division of Rheumatology, Department of Internal Medicine (W.J.M.), University of Michigan Health System, Ann Arbor.

This article has been cited by other articles:

• Sabnani, I., Zucker, M. J., Rosenstein, E. D., Baran, D. A., Arroyo, L. H., Tsang, P., Zubair, M., Rivera, V. (2009). A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology (Oxford) 48: 49-52 [Abstract] [Full Text]  
• Khanna, D., Furst, D. E., Clements, P. J., Tashkin, D. P., Eckman, M. H. (2008). Oral Cyclophosphamide for Active Scleroderma Lung Disease: A Decision Analysis. Med Decis Making 28: 926-937 [Abstract]  
• Wells, A. U., Latsi, P., McCune, W. J. (2007). Daily Cyclophosphamide for Scleroderma: Are Patients with the Most to Gain Underrepresented in this Trial?. Am. J. Respir. Crit. Care Med. 176: 952-953 [Full Text]  
• Tashkin, D. P., Elashoff, R., Clements, P. J., Roth, M. D., Furst, D. E., Silver, R. M., Goldin, J., Arriola, E., Strange, C., Bolster, M. B., Seibold, J. R., Riley, D. J., Hsu, V. M., Varga, J., Schraufnagel, D., Theodore, A., Simms, R., Wise, R., Wigley, F., White, B., Steen, V., Read, C., Mayes, M., Parsley, E., Mubarak, K., Connolly, M. K., Golden, J., Olman, M., Fessler, B., Rothfield, N., Metersky, M., Khanna, D., Li, N., Li, G., for the Scleroderma Lung Study Research Group, (2007). Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease. Am. J. Respir. Crit. Care Med. 176: 1026-1034 [Abstract] [Full Text]  
• Wells, A. U., Hogaboam, C. M. (2007). Update in Diffuse Parenchymal Lung Disease 2006. Am. J. Respir. Crit. Care Med. 175: 655-660 [Full Text]  
• (2006). Restricted Cyclophosphamide Effective for Scleroderma Lung Disease, but at a Cost. Journal Watch Dermatology 2006: 5-5 [Full Text]